OmniRx Health provides physician-supervised medical weight loss programs featuring GLP-1 receptor agonists, GIP/GLP-1 dual agonists, and comprehensive metabolic care. Our licensed providers create personalized weight loss plans based on your labs, health history, and goals — all from home.
Semaglutide (GLP-1): A once-weekly injectable or oral GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and promotes significant weight loss. The active ingredient in Ozempic and Wegovy.
Tirzepatide (GLP-1/GIP): A dual GLP-1 and GIP receptor agonist producing superior weight loss compared to GLP-1 alone. The active ingredient in Mounjaro and Zepbound.
Retatrutide: A next-generation triple receptor agonist targeting GLP-1, GIP, and glucagon pathways for maximum metabolic impact (research use only).
Tesofensine: A serotonin-noradrenaline-dopamine reuptake inhibitor that reduces appetite and supports weight loss through central nervous system pathways.
OmniRx Health is licensed in 44 US states. No in-person office visit required.